- Home
- TBPH vs QURE Comparison
TBPH vs QURE Comparison
Compare TBPH & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- QURE
- Stock Information
- Founded
- TBPH 2013
- QURE 1998
- Country
- TBPH United States
- QURE Netherlands
- Employees
- TBPH N/A
- QURE N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- TBPH Health Care
- QURE Health Care
- Exchange
- TBPH Nasdaq
- QURE Nasdaq
- Market Cap
- TBPH 418.7M
- QURE 432.6M
- IPO Year
- TBPH N/A
- QURE 2007
- Fundamental
- Price
- TBPH $9.47
- QURE $5.78
- Analyst Decision
- TBPH Buy
- QURE Buy
- Analyst Count
- TBPH 4
- QURE 6
- Target Price
- TBPH $13.75
- QURE $17.00
- AVG Volume (30 Days)
- TBPH 220.0K
- QURE 797.9K
- Earning Date
- TBPH 11-12-2024
- QURE 11-05-2024
- Dividend Yield
- TBPH N/A
- QURE N/A
- EPS Growth
- TBPH N/A
- QURE N/A
- EPS
- TBPH N/A
- QURE N/A
- Revenue
- TBPH $63,192,000.00
- QURE $28,587,000.00
- Revenue This Year
- TBPH $6.93
- QURE $157.96
- Revenue Next Year
- TBPH $45.31
- QURE N/A
- P/E Ratio
- TBPH N/A
- QURE N/A
- Revenue Growth
- TBPH 15.93
- QURE N/A
- 52 Week Low
- TBPH $7.44
- QURE $3.73
- 52 Week High
- TBPH $11.71
- QURE $11.35
- Technical
- Relative Strength Index (RSI)
- TBPH 59.09
- QURE 43.09
- Support Level
- TBPH $9.38
- QURE $5.50
- Resistance Level
- TBPH $10.10
- QURE $7.96
- Average True Range (ATR)
- TBPH 0.35
- QURE 0.58
- MACD
- TBPH 0.06
- QURE -0.16
- Stochastic Oscillator
- TBPH 62.75
- QURE 16.48
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.